Intersect ENT, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Intersect ENT, Inc., a subsidiary of Medtronic, is a healthcare equipment company headquartered in Menlo Park, California, specializing in drug-delivery devices for ear, nose, and throat (ENT) conditions. The company manufactures bioabsorbable, steroid-eluting sinus implants such as the PROPEL™ family (PROPEL™, PROPEL™ Mini, PROPEL™ Contour) and SINUVA™ (mometasone furoate) sinus implants that deliver anti-inflammatory medication directly to the sinuses to improve post-operative outcomes and treat chronic rhinosinusitis and nasal polyps. Its product portfolio also includes technology related to drug delivery for sinus surgery and treatment of sinus obstruction. Intersect ENT operates primarily in the United States market, serving hospitals, ambulatory surgery centers, and office-based ENT procedures. The company was founded in 2007 and has developed a strong position in ENT drug delivery implant technology through clinical trials and FDA approvals. The most significant recent change in Intersect ENT's corporate status is its acquisition by Medtronic, completed in May 2022 for approximately $1.1 billion. This acquisition integrated Intersect ENT's PROPEL and SINUVA sinus implant product lines, intellectual property, and Menlo Park facility into Medtronic's Neuroscience Portfolio, expanding Medtronic's comprehensive ENT portfolio worldwide. Concurrently, Intersect ENT divested its Fiagon surgical navigation product line to satisfy regulatory requirements. Post-acquisition, Intersect ENT's products benefit from Medtronic’s global reach, resources, and sales infrastructure supporting expanded market access and innovation pipeline acceleration. Thus, Intersect ENT currently functions as a Medtronic subsidiary focused on innovative sinus implant therapies, delivering localized, clinically proven treatments for chronic ENT conditions, while benefitting from Medtronic’s broader healthcare technology platform and market presence. This strategic alignment aims to enhance patient access, outcomes, and satisfaction globally in the ENT disease space.
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
Orthofix Announces Appointment of Thomas A. West to Board of Directors
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
Why Intersect ENT Shot 12% Higher on Friday
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
Intersect ENT Reports Second Quarter 2021 Financial Results
Medtronic to Acquire Intersect ENT
A Preview Of Intersect ENT's Earnings
Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis